D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 145 Citations 98,119 696 World Ranking 530 National Ranking 324

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

Mark G. Kris focuses on Lung cancer, Internal medicine, Oncology, Cancer and Adenocarcinoma. His Lung cancer study combines topics from a wide range of disciplines, such as Surgery, Radiation therapy, Cancer research and Performance status. In Internal medicine, Mark G. Kris works on issues like Gastroenterology, which are connected to Docetaxel.

His Oncology research integrates issues from Targeted therapy, Carcinoma, Disease and Clinical trial. As part of one scientific family, Mark G. Kris deals mainly with the area of Cancer, narrowing it down to issues related to the MEDLINE, and often Emergency medicine, Intensive care medicine and Common Terminology Criteria for Adverse Events. His research integrates issues of Mutation, KRAS, Lung, Exon and Stage in his study of Adenocarcinoma.

His most cited work include:

  • EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (3644 citations)
  • Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2867 citations)
  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial (2280 citations)

What are the main themes of his work throughout his whole career to date?

Mark G. Kris mostly deals with Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research. His studies link Gastroenterology with Internal medicine. His studies examine the connections between Oncology and genetics, as well as such issues in Docetaxel, with regards to Vinorelbine.

His Lung cancer research incorporates elements of Cancer, Carcinoma and Clinical trial. His Chemotherapy research incorporates themes from Anesthesia, Vomiting and Toxicity. His Cancer research research incorporates themes from Mutation, Tyrosine kinase, Drug resistance and Exon.

He most often published in these fields:

  • Internal medicine (59.00%)
  • Oncology (48.71%)
  • Lung cancer (44.19%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (59.00%)
  • Oncology (48.71%)
  • Lung cancer (44.19%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Lung and Cancer research. His biological study spans a wide range of topics, including Immunohistochemistry, Phases of clinical research, Atezolizumab, Hazard ratio and Stage. His Lung cancer research is multidisciplinary, relying on both Cancer, Targeted therapy, Adenocarcinoma and Mutation, KRAS.

In his research on the topic of Cancer, Cohort is strongly related with Carcinoma. His studies in Cancer research integrate themes in fields like Tyrosine kinase, Mutant, Exon, Drug resistance and Osimertinib. He interconnects Erlotinib and Epidermal growth factor receptor in the investigation of issues within Mutant.

Between 2015 and 2021, his most popular works were:

  • Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial (820 citations)
  • Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment (654 citations)
  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (530 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

His primary areas of investigation include Lung cancer, Internal medicine, Oncology, Cancer and Cancer research. His Lung cancer research integrates issues from Mutation, KRAS, Targeted therapy, Exon and Adenocarcinoma. His research in Oncology intersects with topics in Etoposide, Prospective cohort study, Surgery and Toxicity.

His Cancer research incorporates elements of Genotyping, Adverse effect, Immunology and Retrospective cohort study. His Cancer research study integrates concerns from other disciplines, such as Clinical trial, Navitoclax, Kinase, Drug resistance and Osimertinib. His research investigates the connection with Erlotinib and areas like Adjuvant which intersect with concerns in Epidermal growth factor receptor and Gastroenterology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty.
Proceedings of the National Academy of Sciences of the United States of America (2004)

4838 Citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely.
PLOS Medicine (2005)

3869 Citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

Mark G. Kris;Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch.
JAMA (2003)

3263 Citations

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford.
Journal of Clinical Oncology (2000)

1940 Citations

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima.
Clinical Cancer Research (2013)

1849 Citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller.
PLOS Medicine (2005)

1801 Citations

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher.
Journal of Clinical Oncology (2005)

1727 Citations

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson.
The New England Journal of Medicine (1991)

1677 Citations

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
JAMA (2014)

1262 Citations

Non–Small Cell Lung Cancer

David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang.
Journal of The National Comprehensive Cancer Network (2010)

1231 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mark G. Kris

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 255

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 207

Matthew Meyerson

Matthew Meyerson

Harvard University

Publications: 174

Yi-Long Wu

Yi-Long Wu

Guangdong Provincial People’s Hospital

Publications: 165

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 159

Tetsuya Mitsudomi

Tetsuya Mitsudomi

Kindai University

Publications: 153

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 152

David R. Gandara

David R. Gandara

University of California, Davis

Publications: 146

Frances A. Shepherd

Frances A. Shepherd

Princess Margaret Cancer Centre

Publications: 146

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 138

Lecia V. Sequist

Lecia V. Sequist

Harvard University

Publications: 137

Kazuhiko Nakagawa

Kazuhiko Nakagawa

Kindai University

Publications: 133

Bruce E. Johnson

Bruce E. Johnson

Harvard University

Publications: 125

Myung-Ju Ahn

Myung-Ju Ahn

Samsung Medical Center

Publications: 124

John D. Minna

John D. Minna

The University of Texas Southwestern Medical Center

Publications: 124

Tony Mok

Tony Mok

Chinese University of Hong Kong

Publications: 123

Trending Scientists

Vinko Erceg

Vinko Erceg

Broadcom (United States)

Kent A. Harries

Kent A. Harries

University of Pittsburgh

Fritz Eckstein

Fritz Eckstein

Max Planck Society

Constantinos J. Milios

Constantinos J. Milios

University of Crete

Paul M. G. Curmi

Paul M. G. Curmi

UNSW Sydney

Takao Hayakawa

Takao Hayakawa

National Institutes of Health

Charles F. Thompson

Charles F. Thompson

Illinois State University

Daniel I. Arnon

Daniel I. Arnon

University of California, Berkeley

Richard A. Franklin

Richard A. Franklin

East Carolina University

Lars T. Westlye

Lars T. Westlye

University of Oslo

Seppo Kähkönen

Seppo Kähkönen

Helsinki University Hospital

Barbara G. Shinn-Cunningham

Barbara G. Shinn-Cunningham

Carnegie Mellon University

Kenneth D. R. Setchell

Kenneth D. R. Setchell

Cincinnati Children's Hospital Medical Center

Jeffrey W. Pollard

Jeffrey W. Pollard

University of Edinburgh

Truls Østbye

Truls Østbye

Duke University

Something went wrong. Please try again later.